JAZZ 241018 115.00C (JAZZ241018C115000) Stock Options, News & Quotes

US OptionsDetailed Quotes

JAZZ241018C115000

Watchlist

1.71
+0.61+55.45%

15min DelayClose Sep 27 16:00 ET

1.90High1.55Low

Intraday

5D
Daily

News

Jazz Pharmaceuticals' (NASDAQ:JAZZ) Earnings Have Declined Over Five Years, Contributing to Shareholders 16% Loss
Yahoo FinanceSep 18 08:41 ET
Truist Financial Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating
Moomoo NewsSep 18 07:31 ET · Ratings
Jazz Pharmaceuticals (JAZZ) Gets a Buy From Truist Financial
TipRanksSep 18 07:15 ET
Jazz Pharmaceuticals Says Gastric Cancer Therapy Shows Promise in Mid-Stage Study
MT NewswiresSep 16 08:54 ET
Express News | Jazz Pharmaceuticals PLC - Zanidatamab Plus Chemotherapy Shows Manageable Safety Profile
ReutersSep 16 07:34 ET
Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman
Seeking AlphaSep 15 15:48 ET · Ratings

Comments

Stock_Drift

Sep 16 06:45

$Jazz Pharmaceuticals (JAZZ.US)$

Meltyy

May 22 02:52

Biotech Stock Catalyst Watchlist 👀

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...

Moomoo AI

Mar 27 06:55

Despite Jazz Pharmaceuticals' revenue growth and profitability, its share price drop may signal unresolved issues. The long-term share price weakness could be a bad sign, yet contrarian investors might see a potential turnaround opportunity.

5.0% Earnings Growth Over 3 Years Has Not Materialized Into Gains for Jazz Pharmaceuticals (NASDAQ:JAZZ) Shareholders Over That Period

Moomoo AI

Feb 29 08:59

The low ROE and high debt usage of Jazz Pharmaceuticals make it a less exciting investment at the moment. The company's performance could be impacted if it was unable to borrow as easily in changing credit markets.

Can Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) Improve Its Returns?

Moomoo AI

Jan 7 07:45

Jazz Pharmaceuticals' low P/S ratio is due to slower revenue growth compared to industry trend, leading to discomfort amongst shareholders and stock devaluation. Persisting sluggish growth may decrease P/S ratio even further unless fortunes change.

Jazz Pharmaceuticals Plc's (NASDAQ:JAZZ) Shares Lagging The Industry But So Is The Business